BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133

Benzinga Newsdesk www.benzinga.com Positive 83.7%

Neg 0% Neu 0% Pos 83.7%

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.